for veteran patients in stages 1-3.

  • KidneyIntelX is the only bioprognostic methodology and the only option for early-stage risk assessment in veteran patients with type 2 diabetes and with chronic kidney disease stages 1-3.
  • Demonstrated to be a 3X better predictor of risk vs traditional kidney function measures (eGFR and UACR)

KidneyIntelX begins at the
right starting point.

Only by starting at the earliest stages of diagnosed diabetic kidney disease – and by leveraging the only test demonstrated to identify those select adult veteran patients with type 2 diabetes and chronic kidney disease who are at higher to lower risk for rapid progressive decline in kidney function – will clinicians and veterans reap the greatest benefits from the rest of the treatment plan.